Savient Pharmaceuticals has filed a lawsuit in the US District Court for the District of New Jersey against Sandoz Pharmaceuticals, a Novartis Pharmaceuticals company and Upsher-Smith Laboratories for infringement of Savient’s US patents relating to various methods of using Savient’s Oxandrin (oxandrolone tablets). Oxandrin is Savient’s oral anabolic agent indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infection, or severe trauma.